Bank of Japan Signals Readiness for Near-Term Rate Hike as Inflation Nears Target 
Royalty Pharma Stock Rises After Acquiring Full Evrysdi Royalty Rights from PTC Therapeutics 
Amazon Stock Rebounds After Earnings as $200B Capex Plan Sparks AI Spending Debate 
Sanofi Gains China Approval for Myqorzo and Redemplo, Strengthening Rare Disease Portfolio 
AMD Shares Slide Despite Earnings Beat as Cautious Revenue Outlook Weighs on Stock 
South Korea Assures U.S. on Trade Deal Commitments Amid Tariff Concerns 
China to Add Eli Lilly’s Mounjaro to National Health Insurance in 2025 
FDA Fast-Track Drug Reviews Delayed Over Safety and Efficacy Concerns 
Merck Raises Growth Outlook, Targets $70 Billion Revenue From New Drugs by Mid-2030s 
Uber Ordered to Pay $8.5 Million in Bellwether Sexual Assault Lawsuit 
Global PC Makers Eye Chinese Memory Chip Suppliers Amid Ongoing Supply Crunch 
CK Hutchison Launches Arbitration After Panama Court Revokes Canal Port Licences 
Dollar Near Two-Week High as Stock Rout, AI Concerns and Global Events Drive Market Volatility 
China Extends Gold Buying Streak as Reserves Surge Despite Volatile Prices 
Oil Prices Slide on US-Iran Talks, Dollar Strength and Profit-Taking Pressure 
South Korea’s Weak Won Struggles as Retail Investors Pour Money Into U.S. Stocks 
Novavax raised doubts about the feasibility of continuing its business after struggles in rolling out its coronavirus jab although it has enough money to fund operations.
The COVID-19 vaccine maker, which described the situation as "subject to significant uncertainty," also announced plans to cut spending
On Tuesday, the company reported a loss of $182 million in the fourth quarter, after posting weaker sales than expected at $357 million.
Consequently, Novavax shares plummeted 25 percent in extended trading.
Novavax is currently gearing up for a fall vaccination campaign and said it plans to focus on delivering an updated COVID-19 vaccine.
The Maryland-based Novavax was an early frontrunner in the global vaccine race but fell behind after being hit by manufacturing and regulatory delays.
The company faced delays in regulatory submissions for its jab, which was only authorized in the US in July last year.
Before that, it received authorization from the European Union, United Kingdom, Canada, and Australia.
